NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

11081	Companies
243115	Keywords
171254	Articles
130874	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 11/10/2025 at 14:30, 10 months 14 days ago

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
NanoViricides, Inc. receives approval to start Phase II Clinical Trial of NV-387 for MPox treatment in the DRC. NV-387 shows promise as a broad-spectrum antiviral drug

NanoViricides NV-387 Phase II Clinical Trial Broad-spectrum Antiviral MPOX Treatment
BRIEF

published on 11/05/2025 at 14:35, 10 months 19 days ago

NanoViricides se prépare à une assemblée générale cruciale de ses actionnaires dans un contexte de préoccupations croissantes liées au MPox

NanoViricides NV-387 Essais Cliniques Médicaments Antiviraux Mpox
BRIEF

published on 11/05/2025 at 14:35, 10 months 19 days ago

NanoViricides Prepares for Critical Shareholders Meeting Amidst Rising MPox Concerns

NanoViricides NV-387 Clinical Trials Antiviral Drugs Mpox
PRESS RELEASE

published on 11/05/2025 at 14:30, 10 months 19 days ago

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
NanoViricides, Inc. announces Annual Shareholders Meeting to discuss progress on NV-387, a potential treatment for MPox Clade I. Clinical trials underway

NV-387 Clinical Trials NanoViricides Inc. Annual Shareholders Meeting Mpox Clade I
BRIEF

published on 11/03/2025 at 14:35, 10 months 21 days ago

NanoViricides présentera ses produits à la conférence des investisseurs de Spartan Capital en 2025.

NanoViricides NV-387 Essais Cliniques Médicaments Antiviraux Conférence De La Capitale Spartiate
BRIEF

published on 11/03/2025 at 14:35, 10 months 21 days ago

NanoViricides to Present at Spartan Capital Investor Conference 2025

NanoViricides NV-387 Clinical Trials Antiviral Drugs Spartan Capital Conference
PRESS RELEASE

published on 11/03/2025 at 14:30, 10 months 21 days ago

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
NanoViricides, Inc. to present groundbreaking antiviral drug NV-387 at Spartan Capital Investor Conference. CEO Diwan to update on drug pipeline & Platform Technologies for licensing

NanoViricides NV-387 Clinical Trial Antiviral Drug Spartan Capital Investor Conference
BRIEF

published on 10/29/2025 at 13:50, 10 months 26 days ago

NV-387: A Promising Antiviral Agent for Measles

NanoViricides NV-387 Clinical Trials Antiviral Research Measles Treatment
BRIEF

published on 10/29/2025 at 13:50, 10 months 26 days ago

NV-387 : un agent antiviral prometteur contre la rougeole

NanoViricides NV-387 Essais Cliniques Recherche Antivirale Traitement De La Rougeole
PRESS RELEASE

published on 10/29/2025 at 13:45, 10 months 26 days ago

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
NanoViricides, Inc. announced progress in antiviral research with their drug NV-387 showing potent activity against Measles virus. Clinical trials have shown safety and effectiveness, positioning for emergency use

NanoViricides NV-387 Clinical Trials Antiviral Research Measles Virus

Accesswire

Published on 09/25/2026 at 00:30, 4 hours 3 minutes ago

Viemed Healthcare Announces Adoption of Automatic Securities Disposition Plan by President Michael Moore
Published on 09/25/2026 at 00:15, 4 hours 18 minutes ago

CoTec Holdings Corp. Announces Extension of Private Placement of Unsecured Convertible Debentures
Published on 09/24/2026 at 22:01, 6 hours 32 minutes ago

Fermi Selects CBRE to Operate and Maintain Its First Data Center
Published on 09/24/2026 at 17:45, 10 hours 48 minutes ago

Jo-Jo Announces Resignation of Director
Published on 09/24/2026 at 14:55, 13 hours 38 minutes ago

Nextech3D.ai Surpasses $1 Million in New Customer Contract Value, Expands AI Software Portfolio with KATE and Grows Multi-Year Enterprise Agreements

View all ACCESSWIRE

EQS Group

Published on 09/25/2026 at 02:45, 1 hour 48 minutes ago

Huagui Group: un acteur mondial sur deux marchés aquatiques de plus de 100 milliards de RMB, tandis que la racine de lotus de Honghu se classe au premier rang pour sa teneur en antioxydants
Published on 09/25/2026 at 02:45, 1 hour 48 minutes ago

Huagui Group: A Global Player Across Two RMB100-Billion Aquatic Markets, as Honghu Lotus Root Ranks No. 1 in Antioxidant Content
Published on 09/24/2026 at 20:29, 8 hours 4 minutes ago

EQS-Adhoc: HelloFresh SE expects revenue for Q3 2026 below market expectations and adjusts outlook for the financial year 2026
Published on 09/24/2026 at 19:00, 9 hours 33 minutes ago

HIAG provides a first-hand insight into its strategy and the added value it generates at its Capital Market Day
Published on 09/24/2026 at 18:40, 9 hours 53 minutes ago

EQS-Adhoc: Brockhaus Technologies AG launches public share buyback offer of approx. €90 million for up to 3,592,000 shares

Les Echos

Published on 09/24/2026 at 18:31, 10 hours 2 minutes ago

LNA SANTE : Mise à disposition du rapport financier semestriel 2026
Published on 09/24/2026 at 18:10, 10 hours 23 minutes ago

Financial statements - 30 june 2026
Published on 09/24/2026 at 18:00, 10 hours 33 minutes ago

GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 10 hours 33 minutes ago

GUILLEMOT CORPORATION : Mise à disposition du rapport financier semestriel au 30 juin 2026
Published on 09/24/2026 at 18:00, 10 hours 33 minutes ago

i2S : Résultats 1er semestre 2026

View all LES ECHOS COMFI WIRE